File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib

TitleEfficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib
Authors
Lee, VHFLeung, DENNIS KCChoy, TIM SHINGLam, KOLam, PUI MEILeung, TO WAIKwong, DLW
KeywordsAfatinib
Epidermal growth factor receptor mutation
Erlotinib
Non-small-cell lung cancer
Tyrosine-kinase inhibitor
Issue Date2016
Citation
BMC Cancer, 2016, v. 16, article no. 147 How to Cite?
DOI: http://dx.doi.org/10.1186/s12885-016-2201-9
Persistent Identifierhttp://hdl.handle.net/10722/227212
ISI Accession Number ID
WOS:000371666600002

 

DC FieldValueLanguage
dc.contributor.authorLee, VHF-
dc.contributor.authorLeung, DENNIS KC-
dc.contributor.authorChoy, TIM SHING-
dc.contributor.authorLam, KO-
dc.contributor.authorLam, PUI MEI-
dc.contributor.authorLeung, TO WAI-
dc.contributor.authorKwong, DLW-
dc.date.accessioned2016-07-18T09:09:06Z-
dc.date.available2016-07-18T09:09:06Z-
dc.date.issued2016-
dc.identifier.citationBMC Cancer, 2016, v. 16, article no. 147-
dc.identifier.urihttp://hdl.handle.net/10722/227212-
dc.languageeng-
dc.relation.ispartofBMC Cancer-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectAfatinib-
dc.subjectEpidermal growth factor receptor mutation-
dc.subjectErlotinib-
dc.subjectNon-small-cell lung cancer-
dc.subjectTyrosine-kinase inhibitor-
dc.titleEfficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib-
dc.typeArticle-
dc.identifier.emailLee, VHF: vhflee@hku.hk-
dc.identifier.emailLam, KO: lamkaon@hku.hk-
dc.identifier.emailKwong, DLW: dlwkwong@hku.hk-
dc.identifier.authorityLee, VHF=rp00264-
dc.identifier.authorityLam, KO=rp01501-
dc.identifier.authorityKwong, DLW=rp00414-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1186/s12885-016-2201-9-
dc.identifier.scopuseid_2-s2.0-84959153737-
dc.identifier.hkuros258816-
dc.identifier.volume16-
dc.identifier.spagearticle no. 147-
dc.identifier.epagearticle no. 147-
dc.identifier.eissn1471-2407-
dc.identifier.isiWOS:000371666600002-
dc.identifier.issnl1471-2407-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats